Clinuvel Pharmaceuticals Limited · ASX:CUV
Clinuvel Pharmaceuticals — Shareholder Meeting (November 2008)
17 slides from Clinuvel Pharmaceuticals's shareholder meeting presentation, Nov 13, 2008
Slide 1: Global Prescription Sales 2007
Global Prescription Sales 2007 For personal use only 350 300 250 $US Billions 200 150 100 50 0 North America Europe Japan Source: IMS Health, April 2008
Slide 2: Australian Pharmaceutical Sales
Australian Pharmaceutical Sales For personal use only • Total sales represent approximately 1% of the global market in 2007 • 2005/2006 sales $A 7.91 Billion Source: IMS Health, April 2008 Australian Bureau of Statistics report 8624.0, July 2008
Slide 3: Skin Cancer - Victoria
Skin Cancer- Victoria* For personal use only 2005 2020 61,000 120,000 * Sunday Age 9 November 2008
Slide 4: For personal use only
fee) SOla! USe Onl os ere” ve] Tn a
Slide 5: Brookwood
For personal use only Brookwood
Slide 6: Afamelanotide release from IVR 10, 16 and 20 mg
IVR 10, 16 and 20 mg For personal use only 100 90 80 Afamelanotide Release (%) 70 60 50 40 10 mg 16 mg 30 20 mg 20 10 0 0 1 2 3 4 5 6 7 Days
Slide 7: Amount of afamelanotide released
Amt Released IVR For personal use only 20 18 16 Afamelanotide Released (mg) 14 12 10 8 10 mg 6 16 mg 20 mg 4 2 0 0 1 2 3 4 5 6 7 Days
Slide 8: PK Profiles 10, 16 and 20mg
PK Profiles 10, 16 and 20mg For personal use only 4.0 3.5 Afamelanotide Conc (ng/mL) 3.0 2.5 2.0 10 mg 16 mg 1.5 20 mg 1.0 0.5 0.0 0 2 4 6 8 10 12 14 Days
Slide 9: 10mg 16mg 20mg MD Data
10mg 16mg 20mg MD Data Sun-exposed Sites For personal use only 1.2 1.0 Change in Melanin Density 0.8 0.6 10 mg 0.4 16 mg 20 mg 0.2 0.0 0 10 20 30 40 50 60 Days
Slide 10: PK from CUV009
PK from CUV009 For personal use only 4.5 4 3.5 Afamelanotide Conc (ng/mL) 3 2.5 2 Dose 1 1.5 Dose 2 1 0.5 0 0 5 10 15 20 25 30 Days
Slide 11: MD from CUV009
MD from CUV009 For personal use only 1.4 1.2 Change in Melanin Density 1.0 0.8 0.6 0.4 0.2 0.0 0 10 20 30 40 50 60 70 80 90 Days
Slide 12: List of indications
List of indications For personal use only • Erythropoietic Protoporphyria (EPP) • Photodynamic Therapy (PDT) • Polymorphic Light Eruption (PLE) • Actinic Keratosis / Squamous Cell Carcinoma in OTR • Solar Urticaria (SU)
Slide 13: List of countries – Clinical Studies
List of countries – Clinical Studies For personal use only Australia Italy Austria Norway Belgium Sweden Finland Switzerland France The Netherlands Germany United Kingdom
Slide 14: List of sites – per country
List of sites – per country For personal use only Australia Austria Belgium Finland Adelaide Vienna Brussels Helsinki Brisbane Gent Melbourne France Germany Italy Norway Amiens Berlin Bergamo Bergen Angers Dusseldorf Padua Besancon Kiel Rome Brest Marseilles Paris Sweden Switzerland Netherlands Unit
Slide 15: List of sites per indication
List of sites per indication For personal use only AK – CUV011 EPP - CUV017 PDT – CUV025 Adelaide Bergen Amiens Bergamo Cardiff Angers Berlin Dusseldorf Brest Besancon Helsinki Marseilles Brisbane Maastricht Paris Brussels Manchester Gent Melbourne Kiel Paris Melbourne Rome Padua Rotterdam Zurich St
Slide 16: List of sites per indication
List of sites per indication For personal use only PLE – CUV015 SU – CUV016 Manchester Manchester Melbourne Düsseldorf Vienna Vienna PLE – CUV026 Besancon Brussels Düsseldorf Kiel Manchester Melbourne Rotterdam Vienna
Slide 17: Pending US IND afamelanotide
Pending US IND For personal use only afamelanotide
Clinuvel Pharmaceuticals — Shareholder Meeting (November 2008) on 6ix